VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.

Affiliation

Department of Microbiology and Immunology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, 03756, United States. Electronic address: [Email]

Abstract

V-domain Ig suppressor of T cell activation (VISTA) is a novel checkpoint regulator with limited homology to other B7 family members. The constitutive expression of VISTA on both the myeloid and T lymphocyte lineages coupled to its important role in regulating innate and adaptive immune responses, qualifies VISTA to be a promising target for immunotherapeutic intervention. Studies have shown differential impact of agonistic and antagonistic targeting of VISTA, providing a unique landscape for influencing the outcome of cancer and inflammatory diseases.

Keywords

Agonist,Antagonist,Autoimmunity,Cancer immunotherapy,Immune checkpoint,VISTA,

OUR Recent Articles